Oliwa Jacquie N, Marais Ben J
KEMRI Wellcome Trust Research Programme, Department of Public Health Research, Health Services Unit, Nairobi, Kenya.
Marie Bashir Institute for Infectious Diseases and Biosecurity and The Children's Hospital at Westmead, Sydney Medical School, University of Sydney, Sydney, NSW, Australia.
Paediatr Respir Rev. 2017 Mar;22:23-30. doi: 10.1016/j.prrv.2015.08.004. Epub 2015 Aug 19.
Pneumonia accounted for 15% of the 6.3 million deaths among children younger than five years in 2013, a total of approximately 935,000 deaths worldwide. Routine vaccination against common childhood illnesses has been identified as one of the most cost-effective strategies to prevent death from pneumonia. Vaccine-preventable or potentially preventable diseases commonly linked with respiratory tract infections include Streptococcus pneumoniae, Haemophilus influenza type-b (Hib), pertussis, influenza, measles, and tuberculosis. Although here have been great strides in the development and administration of effective vaccines, the countries that carry the largest disease burdens still struggle to vaccinate their children and newer conjugated vaccines remain out of reach for many. The Global Vaccine Action Plan (GVAP) has identified priority areas for innovation in research in all aspects of immunisation development and delivery to ensure equitable access to vaccines for all.
2013年,在全球630万5岁以下儿童死亡病例中,肺炎占15%,全球共计约93.5万例死亡。针对常见儿童疾病的常规疫苗接种已被视为预防肺炎死亡最具成本效益的策略之一。通常与呼吸道感染相关的可通过疫苗预防或可能预防的疾病包括肺炎链球菌、B型流感嗜血杆菌(Hib)、百日咳、流感、麻疹和结核病。尽管在有效疫苗的研发和接种方面已取得巨大进展,但疾病负担最重的国家仍难以让儿童接种疫苗,许多国家仍无法获得新型结合疫苗。《全球疫苗行动计划》(GVAP)确定了免疫研发和接种各方面研究创新的优先领域,以确保所有人都能公平获得疫苗。